Cargando…

Magnetic Multi-Enzymatic System for Cladribine Manufacturing

Enzyme-mediated processes have proven to be a valuable and sustainable alternative to traditional chemical methods. In this regard, the use of multi-enzymatic systems enables the realization of complex synthetic schemes, while also introducing a number of additional advantages, including the convers...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cruz, Guillermo, Saiz, Laura Pilar, Bilal, Muhammad, Eltoukhy, Lobna, Loderer, Christoph, Fernández-Lucas, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658597/ https://www.ncbi.nlm.nih.gov/pubmed/36362425 http://dx.doi.org/10.3390/ijms232113634

Ejemplares similares

A Multi‐enzyme Cascade for the Biosynthesis of AICA Ribonucleoside Di‐ and Triphosphate
por: Eltoukhy, Lobna, et al.
Publicado: (2021)

A Novel One-Pot Enzyme Cascade for the Biosynthesis of Cladribine Triphosphate
por: Frisch, Julia, et al.
Publicado: (2021)

Immunomodulatory Effects Associated with Cladribine Treatment
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Application of population pharmacokinetics to cladribine
por: Lindemalm, Synnöve, et al.
Publicado: (2005)

Cladribine: Lymphopenia: case report
Publicado: (2021)

Expert-Agreed Practical Recommendations on the Use of Cladribine
por: Meca-Lallana, Virginia, et al.
Publicado: (2022)

Cladribine modifies functional properties of microglia
por: Jørgensen, L. Ø., et al.
Publicado: (2020)

Cladribine: Lymphopenia: 2 case reports
Publicado: (2020)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Erdheim Chester Disease treated successfully with cladribine
por: Azadeh, Natalya, et al.
Publicado: (2016)

Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis
por: Savic, Radojka M., et al.
Publicado: (2017)

Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2018)

The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis
por: Helbig, Grzegorz, et al.
Publicado: (2020)

Green Production of Cladribine by Using Immobilized 2′-Deoxyribosyltransferase from Lactobacillus delbrueckii Stabilized through a Double Covalent/Entrapment Technology
por: Rivero, Cintia Wanda, et al.
Publicado: (2021)

Molecular signature associated with cladribine treatment in patients with multiple sclerosis
por: Fissolo, Nicolas, et al.
Publicado: (2023)

Correction to: Cladribine Tablets: A Review in Relapsing MS
por: Deeks, Emma D.
Publicado: (2019)

Expert opinion on the use of cladribine tablets in clinical practice
por: Sørensen, Per Soelberg, et al.
Publicado: (2020)

COVID-19 in Cladribine-treated patient with multiple sclerosis
por: Haham, Nitsan, et al.
Publicado: (2021)

Review of Transporter Substrate, Inhibitor, and Inducer Characteristics of Cladribine
por: Hermann, Robert, et al.
Publicado: (2021)

Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment
por: Schönfelder, Kristina, et al.
Publicado: (2021)

Biocatalysis: An Eco-Friendly Scenario for the Manufacturing of APIs
por: Fernández-Lucas, Jesús
Publicado: (2023)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies
por: Laurencet, F M, et al.
Publicado: (1999)

Current and Emerging Therapies for the Treatment of Multiple Sclerosis: Focus on Cladribine
por: Schreiner, Teri L., et al.
Publicado: (2012)

Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis
por: Grobost, Vincent, et al.
Publicado: (2014)

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018)

Therapy with cladribine is efficient and safe in patients previously treated with natalizumab
por: Möhn, Nora, et al.
Publicado: (2019)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab
por: Buttari, Fabio, et al.
Publicado: (2021)

Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets
por: Yamout, Bassem I, et al.
Publicado: (2022)

Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets
por: Moiola, Lucia, et al.
Publicado: (2022)

CLIPPERS Responsive to Cladribine as a Durable Steroid-Sparing Agent
por: Thebault, Simon, et al.
Publicado: (2022)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
por: Maltby, Vicki E, et al.
Publicado: (2021)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysis
por: Lübke, Johannes, et al.
Publicado: (2023)

Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
por: Gasperini, Claudio, et al.
Publicado: (2010)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Cladribine Analogues via O(6)-(Benzotriazolyl) Derivatives of Guanine Nucleosides
por: Satishkumar, Sakilam, et al.
Publicado: (2015)

Intrinsic Apoptosis Pathway in Fallopian Tube Epithelial Cells Induced by Cladribine
por: Wawryk-Gawda, Ewelina, et al.
Publicado: (2014)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine
por: Pakpoor, Julia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8lm7ra2kb2ucojdh55mhdockaj